Earnings Preview: Abbott Laboratories and Johnson & Johnson

Abbott Laboratories and Johnson & Johnson are slated to report second quarter earnings this week. Here's what you need to know.

Jul 14, 2014 at 2:30PM

The health care sector in general, and biotech industry in particular, have now shrugged off their earlier first quarter dip. For instance, the iShares Nasdaq Biotech Index (NASDAQ:IBB) has rallied a little over 13% year to date, although this closely watched index remains below its earlier highs this year.

What's key to understand is that this turnaround was ignited by a bevy of strong first quarter earnings reports from top names in the sector. Given the importance of fundamentals to this broad-based rally in the health care sector, let's take a look at what to expect from Abbott Laboratories (NYSE:ABT) and Johnson & Johnson's (NYSE:JNJ) second quarter earnings reports this week. 

IBB Chart

IBB data by YCharts

Abbott will report Wednesday before the bell
Abbott plans to hold a conference call at 8 a.m. EST on July 16 to discuss its second quarter earnings. Wall Street is expecting earnings per share to come in at $0.51 on $5.52 billion in revenue. 

The key issues to pay attention to are growth in emerging markets across business segments and volatility in currency exchange that could have a major influence on profitability. Its Established Pharmaceuticals business was particularly affected by currency fluctuations in the first quarter, leading to a 5.9% drop in revenue. 

Turning to specific issues to keep an eye on, investors should watch for continued growth in Abbott's molecular diagnostic tests for core infectious diseases, which management pegged as an area with significant expansion opportunities last quarter. Abbott's vascular business should also play an important role this quarter, following the launch of a diversity of new products including Supera and MitraClip and the rapid growth of this business in key emerging markets like India. 

Abbott should also benefit this quarter from the resolution of the disruption in its international nutrition business and supply issues for some Established Pharmaceuticals products that negatively affected sales in the prior quarter.

Johnson & Johnson will report Tuesday before the bell
Johnson & Johnson will host a conference call at 8:30 a.m. EST on July 15 to provide details on its second quarter. Although the consensus on the Street stands at $1.55 for earnings per share on $18.94 billion in revenue, we've already heard a number of analysts state they they expect the pharma giant to beat these numbers, based mainly on the strong sales in its pharmaceutical segment. 

In terms of pharma sales, the Street will definitely take a keen interest in the sales of J&J's new hepatitis C drug Olysio--after its launch blew away initial expectations in the first-quarter and caught most analysts flat-footed. Given that Sovaldi's prescriptions look like they grew at a nice clip this quarter and the bulk of Olysio's sales came as co-prescriptions with Sovaldi, I think the general optimism for strong quarter over quarter growth for Olysio is justified.

Next up, the Street will be scrutinizing sales of J&J's red-hot prostate cancer drug, Zytiga. Although Zytiga has been one of the company's fastest growing pharma products lately, Medivation (NASDAQ:MDVN) and Astellas Pharma's Xtandi has captured market share at breakneck pace as well. Zytiga's sales might pull back this quarter, as competition becomes a bigger factor.

Foolish wrap-up
These two top health care names help to kick off earnings season this week, with both likely to top consensus -- or at least meet estimates. That being said, Abbott and J&J could report negative surprises in their earnings this week. Abbott's internationally oriented business exposes it in a major way to volatility in currency exchange and J&J's flagship prostate cancer drug Zytiga should start to feel the effects of competition in the near future. In sum, these are pivotal issues to be on the lookout for this quarter that could have far-reaching impacts across the health care sector. 

Leaked: This coming blockbuster could make even Johnson & Johnson jealous
The best investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.


George Budwell owns shares of Johnson & Johnson. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information